The Biological and Clinical Landscape of Parkinson’s Disease
In his presentation for the 2021 Neuroscience Symposium, Dr. Carlos Singer, Professor of Neurology at the Miller School of Medicine, challenges the historical "stereotype" of Parkinson’s Disease (PD). He notes that the classic 1886 illustration by Sir William Gowers, while foundational, often masks the true diversity of the disease.
Introduction: Beyond the Stereotype
Dr. Singer notes that PD affects different genders, ethnic groups, and ages with varied rates of progression. He categorizes the clinical phenotypes into three primary types: mild motor predominant (younger patients with slow progression), intermediate, and advanced/rapidly progressive, the latter of which often involves severe motor disability and cognitive decline.
The Clinical Core: Motor and Non-Motor Burdens
The diagnosis of PD is anchored in a motor triad, with bradykinesia (slowness of movement) as the "main actor," combined with either rigidity or tremor. However, Dr. Singer emphasizes that tremor is absent in approximately 20% of cases.
Crucially, the "maladies" of PD extend far beyond motor symptoms. Dr. Singer highlights a heavy non-motor burden that often accrues over years:
- Neuropsychiatric: Anxiety, depression, and apathy.
- Sleep Disorders: Specifically REM Behavior Disorder (RBD), which can precede motor symptoms by years.
- Autonomic/Sensory: Constipation and anosmia (loss of smell) are frequently the earliest indicators of the disease.
The Pathological Progression: The Braak Hypothesis
A significant portion of the lecture is dedicated to the pathology of the disease, specifically the role of alpha-synuclein—a protein that aggregates to form Lewy bodies within surviving neurons. Dr. Singer explains the Braak Staging System, a landmark hypothesis published by Heiko Braak in 2003.
Braak Staging Progression
- Stage 1: Olfactory bulb and dorsal motor nucleus of the vagus (Loss of smell/constipation).
- Stage 2: Locus coeruleus and raphe nuclei (Depression/sleep issues).
- Stage 3: Substantia nigra (Classic motor symptoms).
- Stages 4-6: Mesocortex and neocortex (Cognitive decline/dementia).
Etiology: The Gene-Environment Interaction
Dr. Singer describes PD as a spectrum of interactions between genetics and the environment. While only 10% of cases are "purely" genetic (such as mutations in the SNCA or PRKN genes), many patients carry genetic risk factors like the GBA or LRRK2 variants.
Environmental Triggers: Exposure to pesticides (rotenone), chlorinated solvents (trichloroethylene), and heavy metals (manganese) are identified as potential catalysts for oxidative stress and mitochondrial dysfunction.
The Prion Hypothesis: One of the most compelling modern theories discussed is the "cell-to-cell transfer" of misfolded alpha-synuclein. Dr. Singer explains that these proteins may act like prions, where one misfolded protein "seeds" the misfolding of others in neighboring cells.
Future Horizons in Treatment
The lecture concludes with a look at therapeutic avenues aimed at disease modification rather than just symptom management:
- Reduce alpha-synuclein production or increase its degradation.
- Enhance lysosomal function by promoting GCase enzyme activity.
- Inhibit LRRK2 activity to decrease excess kinase activity.
External Context and References
By understanding PD as a "rostral-caudally ascending process" driven by protein misfolding, Dr. Singer provides a framework for a future where treatments move from symptom management to true disease-modifying therapies.